Trial Profile
Phase II Study of the Histone-deacetylase Inhibitor GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Patients With JAK2V617F Positive Polycythemia Vera Non-responder to Hydroxyurea Monotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Givinostat (Primary) ; Hydroxycarbamide
- Indications Polycythaemia vera
- Focus Therapeutic Use
- 16 Dec 2011 New trial record
- 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.